Results
Cohance Lifesciences Q1FY27 Revenue Down 23.1% YoY
Cohance Lifesciences reported Q1FY27 revenue decline of 23.1% YoY to ₹4,223 million with EBITDA margin contraction due to product mix and lower CDMO contribution.
Management confirmed Q1 as weakest qu
